Pozen, Inc. – Product Pipeline Review – 2013
Summary
Global Market Direct’s pharmaceuticals report, “Pozen, Inc. - Product Pipeline Review - 2013” provides data on the Pozen, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Pozen, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Pozen, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Summary
Global Market Direct’s pharmaceuticals report, “Pozen, Inc. - Product Pipeline Review - 2013” provides data on the Pozen, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Pozen, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Pozen, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Pozen, Inc. - Brief Pozen, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Pozen, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Pozen, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Pozen, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Pozen, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Pozen, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Pozen, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Pozen, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Pozen, Inc. and identify potential opportunities in those areas.
Pozen, Inc. Snapshot
Pozen, Inc. Overview
Key Information
Key Facts
Pozen, Inc. – Research and Development Overview
Key Therapeutic Areas
Pozen, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Pozen, Inc. – Pipeline Products Glance
Pozen, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Pozen, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Pozen, Inc. – Drug Profiles
(aspirin + omeprazole)
Product Description
Mechanism of Action
R&D Progress
(aspirin EC + omeprazole IR)
Product Description
Mechanism of Action
R&D Progress
(enteric coated aspirin + immediate release omeprazole)
Product Description
Mechanism of Action
R&D Progress
(omeprazole + asprin) + [clopidogrel bisulfate]
Product Description
Mechanism of Action
R&D Progress
MT-400
Product Description
Mechanism of Action
R&D Progress
PA-65020
Product Description
Mechanism of Action
R&D Progress
Pozen, Inc. – Pipeline Analysis
Pozen, Inc. – Pipeline Products by Therapeutic Class
Pozen, Inc. – Pipeline Products by Route of Administration
Pozen, Inc. – Pipeline Products By Mechanism of Action
Pozen, Inc. – Recent Pipeline Updates
Pozen, Inc. - Dormant Projects
Pozen, Inc. – Company Statement
Pozen, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Pozen, Inc., Recent Developments
Pozen, Inc.- Press Release
Mar 27, 2013: Pozen Submits New Drug Application For PA32540
Mar 27, 2013: Pozen Submits New Drug Application For PA8140
Feb 08, 2013: Pozen Presents Positive PA32540 Phase III Data At 2013 International Stroke Conference
Nov 14, 2010: POZEN Presents PA32540 Phase I Data At American Heart Association Scientific Sessions
May 06, 2010: POZEN Reports PA65020 Significantly Reduces Incidence Of Upper GI Damage In Healthy Adults
Financial Deals Landscape
Pozen, Inc., Deals Summary
Pozen, Inc., Pharmaceuticals & Healthcare, Deal Details
Licensing Agreements
Pozen Enters Into Licensing Agreement With Desitin Arzneimittel For MT 400
POZEN Enters Into Licensing Agreement With Cilag GmbH For MT 400
Equity Offering
POZEN Files Registration Statement For Public Offering Of Shares For $31.2 Million
Asset Transactions
CPP Investment Acquires Royalties Of Treximet From POZEN
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Pozen, Inc., Key Information
Pozen, Inc., Key Facts
Pozen, Inc. – Pipeline by Indication, 2013
Pozen, Inc. – Pipeline by Stage of Development, 2013
Pozen, Inc. – Monotherapy Products in Pipeline, 2013
Pozen, Inc. – Combination Treatment Modalities in Pipeline, 2013
Pozen, Inc. – Filed, 2013
Pozen, Inc. – Phase III, 2013
Pozen, Inc. – Phase I, 2013
Pozen, Inc. – Pipeline By Therapeutic Class, 2013
Pozen, Inc. – Pipeline By Route of Administration, 2013
Pozen, Inc. – Pipeline Products By Mechanism of Action, 2013
Pozen, Inc. – Recent Pipeline Updates, 2013
Pozen, Inc. - Dormant Developmental Projects,2013
Pozen, Inc., Subsidiaries
Pozen, Inc., Deals Summary
Pozen Enters Into Licensing Agreement With Desitin Arzneimittel For MT 400
POZEN Enters Into Licensing Agreement With Cilag GmbH For MT 400
POZEN Files Registration Statement For Public Offering Of Shares For $31.2 Million
CPP Investment Acquires Royalties Of Treximet From POZEN
LIST OF FIGURES
Pozen, Inc. – Pipeline by Indication, 2013
Pozen, Inc. – Pipeline by Stage of Development, 2013
Pozen, Inc. – Monotherapy Products in Pipeline, 2013
Pozen, Inc. – Combination Treatment Modalities in Pipeline, 2013
Pozen, Inc. – Pipeline By Therapeutic Class, 2013
Pozen, Inc. - Pipeline Products By Mechanism of Action, 2013
Pozen, Inc. Overview
Key Information
Key Facts
Pozen, Inc. – Research and Development Overview
Key Therapeutic Areas
Pozen, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Pozen, Inc. – Pipeline Products Glance
Pozen, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Pozen, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Pozen, Inc. – Drug Profiles
(aspirin + omeprazole)
Product Description
Mechanism of Action
R&D Progress
(aspirin EC + omeprazole IR)
Product Description
Mechanism of Action
R&D Progress
(enteric coated aspirin + immediate release omeprazole)
Product Description
Mechanism of Action
R&D Progress
(omeprazole + asprin) + [clopidogrel bisulfate]
Product Description
Mechanism of Action
R&D Progress
MT-400
Product Description
Mechanism of Action
R&D Progress
PA-65020
Product Description
Mechanism of Action
R&D Progress
Pozen, Inc. – Pipeline Analysis
Pozen, Inc. – Pipeline Products by Therapeutic Class
Pozen, Inc. – Pipeline Products by Route of Administration
Pozen, Inc. – Pipeline Products By Mechanism of Action
Pozen, Inc. – Recent Pipeline Updates
Pozen, Inc. - Dormant Projects
Pozen, Inc. – Company Statement
Pozen, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Pozen, Inc., Recent Developments
Pozen, Inc.- Press Release
Mar 27, 2013: Pozen Submits New Drug Application For PA32540
Mar 27, 2013: Pozen Submits New Drug Application For PA8140
Feb 08, 2013: Pozen Presents Positive PA32540 Phase III Data At 2013 International Stroke Conference
Nov 14, 2010: POZEN Presents PA32540 Phase I Data At American Heart Association Scientific Sessions
May 06, 2010: POZEN Reports PA65020 Significantly Reduces Incidence Of Upper GI Damage In Healthy Adults
Financial Deals Landscape
Pozen, Inc., Deals Summary
Pozen, Inc., Pharmaceuticals & Healthcare, Deal Details
Licensing Agreements
Pozen Enters Into Licensing Agreement With Desitin Arzneimittel For MT 400
POZEN Enters Into Licensing Agreement With Cilag GmbH For MT 400
Equity Offering
POZEN Files Registration Statement For Public Offering Of Shares For $31.2 Million
Asset Transactions
CPP Investment Acquires Royalties Of Treximet From POZEN
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Pozen, Inc., Key Information
Pozen, Inc., Key Facts
Pozen, Inc. – Pipeline by Indication, 2013
Pozen, Inc. – Pipeline by Stage of Development, 2013
Pozen, Inc. – Monotherapy Products in Pipeline, 2013
Pozen, Inc. – Combination Treatment Modalities in Pipeline, 2013
Pozen, Inc. – Filed, 2013
Pozen, Inc. – Phase III, 2013
Pozen, Inc. – Phase I, 2013
Pozen, Inc. – Pipeline By Therapeutic Class, 2013
Pozen, Inc. – Pipeline By Route of Administration, 2013
Pozen, Inc. – Pipeline Products By Mechanism of Action, 2013
Pozen, Inc. – Recent Pipeline Updates, 2013
Pozen, Inc. - Dormant Developmental Projects,2013
Pozen, Inc., Subsidiaries
Pozen, Inc., Deals Summary
Pozen Enters Into Licensing Agreement With Desitin Arzneimittel For MT 400
POZEN Enters Into Licensing Agreement With Cilag GmbH For MT 400
POZEN Files Registration Statement For Public Offering Of Shares For $31.2 Million
CPP Investment Acquires Royalties Of Treximet From POZEN
LIST OF FIGURES
Pozen, Inc. – Pipeline by Indication, 2013
Pozen, Inc. – Pipeline by Stage of Development, 2013
Pozen, Inc. – Monotherapy Products in Pipeline, 2013
Pozen, Inc. – Combination Treatment Modalities in Pipeline, 2013
Pozen, Inc. – Pipeline By Therapeutic Class, 2013
Pozen, Inc. - Pipeline Products By Mechanism of Action, 2013
